EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

NSE and ProGRP Are Promising Markers for Diagnosis, Efficacy Evaluation, Follow‐Up Monitoring, and Prognosis of Small Cell Esophageal Carcinoma

Di Liu iD, Dan Wu, Jianjiao Ni, Junhua Zhang iD, Suhong Xie

Thoracic Cancer · 2025

DOI: 10.1111/1759-7714.70026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Di Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Biomarkers, Tumor, Phosphopyruvate Hydratase, Peptide Fragments. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To investigate the clinical implications of serum carcinoembryonic antigen (CEA), neuron specific enolase (NSE), and pro‐gastrin‐releasing peptide (ProGRP) in small cell esophageal carcinoma (SCEC).

Methods

Receiver operating characteristic (ROC) curves were used to determine the area under the curve (AUC), sensitivity, and specificity of serum markers for differentiating SCEC from patients with esophageal squamous carcinoma (ESCC), esophageal adenocarcinoma (EAC) and healthy subjects.

Results

The combination of ProGRP and NSE demonstrated significant diagnostic efficacy in distinguishing SCEC from ESCC, EAC, and healthy individuals. After treatment, serum levels of ProGRP, NSE, and CEA in SCEC patients with disease control decreased significantly compared to pre‐treatment levels. Conversely, the serum levels of ProGRP and NSE in patients with disease progression after treatment were significantly increased compared to those before treatment. Compared with those in the follow‐up phase, the levels of ProGRP, NSE, and CEA significantly increased after tumor progression in SCEC patients. This study further exhibited that serum levels of ProGRP above 45.15 pg/mL and NSE above 14.70 ng/mL during follow‐up after first‐line treatment in SCEC patients were associated with poor progression‐free survival (PFS). Moreover, significant associations were observed between baseline serum concentrations of ProGRP, NSE, CEA and both PFS and cancer‐specific survival (CSS) in SCEC patients.

Conclusions

ProGRP and NSE have significant value in the diagnosis and differential diagnosis of SCEC, and are also associated with the clinical stage and prognosis of SCEC patients, as well as are effective indicators for evaluating therapeutic efficacy and disease recurrence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsBiomarkers, TumorPhosphopyruvate HydratasePeptide FragmentsCarcinoma, Small CellHumansMaleFemalePrognosisMiddle AgedAgedFollow-Up StudiesRecombinant Proteins

Stichwörter der Autor:innen

diagnosisefficacyprognosisrelapseserum tumor markersmall cell esophageal carcinoma

Substanzen

Biomarkers, TumorPhosphopyruvate Hydratasepro-gastrin-releasing peptide (31-98)Peptide FragmentsRecombinant Proteins

Autor:innen und Institutionen

  • Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Shanghai Key Laboratory of Radiation Oncology, Shanghai, China.
  • Facial Plastic and Reconstructive Surgery, Eye & ENT Hospital of Fudan University, Shanghai, China.
  • Department of Ophthalmology and Visual Science, Eye & ENT Hospital of Fudan University, Shanghai, China.
  • Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.

ORCID-Profile: Di Liu, Junhua Zhang

Zitieren

APA

Liu, D., Wu, D., Ni, J., Zhang, J., & Xie, S. (2025). NSE and ProGRP Are Promising Markers for Diagnosis, Efficacy Evaluation, Follow‐Up Monitoring, and Prognosis of Small Cell Esophageal Carcinoma. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70026

Vancouver

Liu D, Wu D, Ni J, Zhang J, Xie S. NSE and ProGRP Are Promising Markers for Diagnosis, Efficacy Evaluation, Follow‐Up Monitoring, and Prognosis of Small Cell Esophageal Carcinoma. Thoracic Cancer. 2025. doi:10.1111/1759-7714.70026

BibTeX
@article{Liu2025,
  author = {Liu, Di and Wu, Dan and Ni, Jianjiao and Zhang, Junhua and Xie, Suhong},
  title = {NSE and ProGRP Are Promising Markers for Diagnosis, Efficacy Evaluation, Follow‐Up Monitoring, and Prognosis of Small Cell Esophageal Carcinoma},
  journal = {Thoracic Cancer},
  year = {2025},
  doi = {10.1111/1759-7714.70026}
}
Kostenlos starten →